ICON experts frequently author or contribute to industry trade press. The following are some recent articles.
10 Professionals Predict the Future of Clinical Trials
Read ICON expert Sarah Ikard's take on the innovative role patient centricity may play in the evolution of future trials here.
The Long Journey Towards Patient Centricity
ICON experts discuss the evolution of patient reported outcomes & the role of patient outcome research in informing payers, patients, clinicians & regulators.
Adoptive Cell Transfer (ACT) Clinical Trials: The Long Road
ICON's Martin Lachs & Brandon Fletcher discuss ACT clinical trials in this July 2019 DDN News article.
Leveraging Novel Therapeutics & Diagnostic Assays
Marisa Pearce at Molecular MD, an ICON company, argues that, although immunotherapy is nothing new, it has much untapped potential yet to be explored.
Technology the Key for Improving Trial Efficiencies & Retention
Learn how the use of technology has become ubiquitous in clinical trials as the industry looks to streamline and improve processes.
Oncology & ASCO 2019: Moving from Autologous to Allogeneic ACT Paradigms
ACT approaches have the possibilities of therapies with reduced safety concerns, a higher therapeutic index, as well as breadth of targets including solid tumours. More details here.
Increasing Predictability in Patient Recruitment
PharmaVOICE article featuring commentary from E.B. McLindon on the increasing complexity of protocol design & the importance of assessing patient & site burden.
The Perverse Incentive: A Unified Approach to Patient Engagement
Matthew McCarty at ICON establishes a greater unified approach to patient engagement, retention, and compliance through patient-facing technologies.
ICON Acquires MeDiNova Research Site in Europe & Africa
ICON has acquired a majority shareholding in MeDiNova Research, a site network with research sites in Europe and Africa.
The Digital Trial: How Technology Is Changing Trial Design, Start-Up And Close-Out
In this Clinical Informatics News article, featuring commentary from ICON's Marie McCarthy, leveraging technology to accelerate study close-out is discussed.